OR WAIT null SECS
CALIXAR and VirPath use new manufacturing techniques to create a vaccine for the pandemic flu, influenza A (H1N1), available in 2015.
CALIXAR, a start-up company providing services focused on membrane proteins, and VirPath, an academic lab specializing in the study of influenza viruses, announced on Sept. 23, 2014 the use of new manufacturing techniques to develop an influenza A (H1N1) vaccine.
The partners’ new formulation of vaccine antigens is designed to prevent influenza A (H1N1) virus, or pandemic flu. The formulation showed improved performance compared to other vaccines on the market. CALIXAR developed the technology and chemistry to split the virus’ membranes. VirPath’s egg-derived antigens formulations, which were extracted with CALIXAR’s technology, are at least six times more active than currently marketed vaccines, in terms of hemagglutinin immunogenicity and in-vivo protection, according to a CALIXAR press release.
“We will offer the influenza technology for licensing early 2015. We are also looking at other applications in the vaccine industry using the same chemistry and biochemistry approaches,” said Chairman and CEO of CALIXAR, DR. Emmanuel Dejean, in the release.